Who are [89Zr]Zr-crefmirlimab berdoxam's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ibritumomab Tiuxetan + Maintenance.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/89zr-zr-crefmirlimab-berdoxam.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

[89Zr]Zr-crefmirlimab berdoxam — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

[89Zr]Zr-crefmirlimab berdoxam (89zr-zr-crefmirlimab-berdoxam) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radiolabeled Monoclonal Antibody. Area: Oncology.

marketed Radiolabeled Monoclonal Antibody Fibroblast Activation Protein (FAP) Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

[89Zr]Zr-crefmirlimab berdoxam (89zr-zr-crefmirlimab-berdoxam) — Pfizer.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
[89Zr]Zr-crefmirlimab berdoxam TARGET	89zr-zr-crefmirlimab-berdoxam	Pfizer	marketed	Radiolabeled Monoclonal Antibody	Fibroblast Activation Protein (FAP)	Not specified
Ibritumomab Tiuxetan + Maintenance	Ibritumomab Tiuxetan + Maintenance	Fondazione Italiana Linfomi - ETS	phase 3	Radiolabeled monoclonal antibody (anti-CD20)	CD20

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radiolabeled Monoclonal Antibody class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). [89Zr]Zr-crefmirlimab berdoxam — Competitive Intelligence Brief. https://druglandscape.com/ci/89zr-zr-crefmirlimab-berdoxam. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab